Senzime AB (publ) (SEZI.ST)
SEK 5.64
(-1.05%)
SEK 5.64
(-1.05%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 11.46 Million SEK | -12.08% |
| 2022 | 13.04 Million SEK | 698.23% |
| 2021 | 1.63 Million SEK | -31.8% |
| 2020 | 2.39 Million SEK | 517.53% |
| 2019 | 388 Thousand SEK | 42.12% |
| 2018 | 273 Thousand SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | -100.0% |
| 2015 | 37 Thousand SEK | -69.42% |
| 2014 | 121 Thousand SEK | -34.59% |
| 2013 | 185 Thousand SEK | -38.44% |
| 2012 | 300.5 Thousand SEK | -44.74% |
| 2011 | 543.81 Thousand SEK | -81.93% |
| 2010 | 3.01 Million SEK | -18.85% |
| 2009 | 3.7 Million SEK | -3.62% |
| 2008 | 3.84 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 11.22 Million SEK | -2.14% |
| 2024 Q2 | 24.07 Million SEK | 114.47% |
| 2023 FY | 11.46 Million SEK | -12.08% |
| 2023 Q4 | 11.46 Million SEK | -2.87% |
| 2023 Q1 | 12.24 Million SEK | -6.15% |
| 2023 Q2 | 12.47 Million SEK | 1.9% |
| 2023 Q3 | 11.8 Million SEK | -5.35% |
| 2022 Q3 | 14.66 Million SEK | 643.06% |
| 2022 Q4 | 13.04 Million SEK | -11.08% |
| 2022 Q1 | 1.39 Million SEK | -14.63% |
| 2022 FY | 13.04 Million SEK | 698.23% |
| 2022 Q2 | 1.97 Million SEK | 41.51% |
| 2021 FY | 1.63 Million SEK | -31.8% |
| 2021 Q2 | 1.37 Million SEK | -13.18% |
| 2021 Q1 | 1.57 Million SEK | -34.14% |
| 2021 Q3 | 1.72 Million SEK | 25.69% |
| 2021 Q4 | 1.63 Million SEK | -5.11% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q1 | - SEK | -100.0% |
| 2020 FY | 2.39 Million SEK | 517.53% |
| 2020 Q4 | 2.39 Million SEK | -13.53% |
| 2020 Q3 | 2.77 Million SEK | 0.0% |
| 2019 Q4 | 388 Thousand SEK | 0.0% |
| 2019 FY | 388 Thousand SEK | 42.12% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | -100.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | 273 Thousand SEK | 0.0% |
| 2018 Q4 | 790 Thousand SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | 1.27 Million SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 FY | - SEK | -100.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2015 FY | 37 Thousand SEK | -69.42% |
| 2015 Q3 | 37 Thousand SEK | -50.0% |
| 2015 Q4 | 37 Thousand SEK | 0.0% |
| 2015 Q1 | 74 Thousand SEK | -38.84% |
| 2015 Q2 | 74 Thousand SEK | 0.0% |
| 2014 FY | 121 Thousand SEK | -34.59% |
| 2014 Q4 | 121 Thousand SEK | 0.0% |
| 2014 Q3 | 121 Thousand SEK | -18.24% |
| 2014 Q2 | 148 Thousand SEK | 0.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2013 Q4 | 185 Thousand SEK | 0.0% |
| 2013 Q2 | 178 Thousand SEK | 0.0% |
| 2013 Q1 | 178 Thousand SEK | -40.77% |
| 2013 FY | 185 Thousand SEK | -38.44% |
| 2012 Q4 | 300.5 Thousand SEK | 0.0% |
| 2012 FY | 300.5 Thousand SEK | -44.74% |
| 2012 Q2 | 146.84 Thousand SEK | 0.0% |
| 2011 FY | 543.81 Thousand SEK | -81.93% |
| 2011 Q4 | 543.81 Thousand SEK | 0.0% |
| 2011 Q2 | 2.68 Million SEK | 0.0% |
| 2010 Q4 | 3.01 Million SEK | 0.0% |
| 2010 Q2 | 3.24 Million SEK | 0.0% |
| 2010 FY | 3.01 Million SEK | -18.85% |
| 2009 Q4 | 3.7 Million SEK | 0.0% |
| 2009 FY | 3.7 Million SEK | -3.62% |
| 2008 FY | 3.84 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.289% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.289% |
| Arcoma AB | 3.87 Million SEK | -196.101% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 95.08% |
| BICO Group AB (publ) | 1.85 Billion SEK | 99.381% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 93.096% |
| CellaVision AB (publ) | 64.7 Million SEK | 82.276% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -2425.991% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -537.111% |
| Duearity AB (publ) | 10.58 Million SEK | -8.373% |
| Dignitana AB (publ) | 19.1 Million SEK | 39.971% |
| Episurf Medical AB (publ) | 5.2 Million SEK | -120.538% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.858% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | -39.012% |
| Iconovo AB (publ) | 7.72 Million SEK | -48.455% |
| Integrum AB (publ) | 6.42 Million SEK | -78.513% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -5466.342% |
| Mentice AB (publ) | 9.55 Million SEK | -19.996% |
| OssDsign AB (publ) | 3.15 Million SEK | -264.063% |
| Paxman AB (publ) | 13.57 Million SEK | 15.49% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 44.682% |
| SciBase Holding AB (publ) | 6.79 Million SEK | -68.721% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 63.923% |
| Sedana Medical AB (publ) | 4.3 Million SEK | -166.326% |
| SpectraCure AB (publ) | 6.71 Million SEK | -70.731% |
| Stille AB | 62.94 Million SEK | 81.78% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.451% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 63.521% |